Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model

International Journal of Antimicrobial Agents

Volumn 20, Issue 3, 2002, Pages 201-205

  Portnoy, Yury A ^a   Vostrov, Sergey N ^a   Lubenko, Irene Yu ^a   Zinner, Stephen H ^b   Firsov, Alexander A ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Ciprofloxacin; Gemifloxacin; In vitro models; Pharmacodynamics

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HAEMOPHILUS INFLUENZAE; MATHEMATICAL ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; SPECIES DIFFERENTIATION; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HALF-LIFE; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NAPHTHYRIDINES; SPECIES SPECIFICITY;

EID: 0036710080     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00131-0     Document Type: Article

References (24)

1. Firsov A.A., Chernykh V.M., Navashin S.M. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob. Agents Chemother. 34:1991;1312-1317.
2. Firsov A.A., Vostrov S.N., Kononenko O.V., Lubenko I.Y., Zinner S.H. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in vitro dynamic model. J. Antimicrob. Chemother. 43:1999;483-490.
3. Vostrov S.N., Kononenko O.V., Lubenko I.Y., Zinner S.H., Firsov A.A. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob. Agents Chemother. 44:2000;879-884.
4. Firsov A.A., Lubenko I.Y., Vostrov S.N., Kononenko O.V., Zinner S.H., Portnoy Y.A. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J. Antimicrob. Chemother. 46:2000;725-732.
5. Firsov A.A., Zinner S.H., Lubenko I.Y., Vostrov S.N. Gemifloxacin and ciprofloxacin pharmacodynamics in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int. J. Antimicrob. Agents. 16:2000;407-414.
6. Zinner S.H., Vostrov S.N., Lubenko I.Y., Portnoy Y.A., Cornaglia G., Firsov A.A. Comparative antistaphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn. Microbiol. Infect. Dis. 40:(4):2001;167-171.
7. Firsov A.A., Zinner S.H. Use of modeling techniques to aid in antibiotic selection. Curr. Infect. Dis. Rep. 3:2001;35-43.
8. Firsov A.A., Zinner S.H., Vostrov S.N., Lubenko I.Y. AUC/MIC breakpoints of moxifloxacin relative to levofloxacin predicted with in vitro dynamic models: single dose versus multiple dose simulations. Clin. Microbiol. Infect. 6:(Suppl. 1):2000;199.
9. Forrest A., Chodosh S., Amantea M.A., Collins D.A., Schentag J.J. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40:(Suppl. A):1997;45-57.
10. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279:1998;2.
11. Firsov A.A., Vostrov S.N., Shevchenko A.A., Zinner S.H., Portnoy Y.A. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob. Agents Chemother. 42:1998;2841-2847.
12. Allen A., Bygate E., Oliver S., et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 44:2000;1604-1608.
13. Bergan T, Thorsteinsson SB. Pharmacokinetics and bioavailability of ciprofloxacin, In: Neu HC, Weuta H, editors. proceedings of the first international ciprofloxacin workshop. Amsterdam: Excer Med, 1986, p. 111-121.
14. Hoffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27:1985;375-379.
15. Wise R., Lister D., McNulty C.A.M., Griggs D., Andrews J.M. The comparative pharmacokinetics of five quinolones. J. Antimicrob. Chemother. 18:(Suppl D):1986;71-81.
16. Firsov A.A., Shevchenko A.A., Vostrov S.N., Zinner S.H. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob. Agents Chemother. 42:1998;659-665.
17. Rustige C., Wiedemann B. Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. Antimicrob. Agents Chemother. 34:1990;1107-1111.
18. Wiedemann B., Wiegand I., Pfeil E. In vitro pharmacology of modern quinolones against respiratory tract phatogens. Int. J. Antimicrob. Agents. 47:(Suppl. S1):2001;41.
19. Nakashima M., Uematsu T., Kosuge K., et al. Single- and multiple dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:1995;2635-2640.
20. Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:1997;101-119.
21. Stass H.H., Dalhoff A., Kubitza D., Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:1998;2060-2065.
22. Felmingham D., Robbins M.J., Dencer C., Salman H., Mathias I., Ridgway G.L. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp. J. Antimicrob. Chemother. 44:(Suppl. A):1999;131.
23. Firsov A.A., Lubenko I.Y., Portnoy Y.A., Zinner S.H., Vostrov S.N. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob. Agents Chemother. 45:2001;927-931.
24. Wiedemann B. Evaluation of data from susceptibility testing. Int. J. Antimicrob. Agents. 10:1998;89-90.